Merck & Co Maps Out Route To $10bn Cardiovascular Franchise
Eight Approvals Targeted By 2030
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.
You may also be interested in...
VC partner Colleen Cuffaro talked to Scrip about how the investment firm plans to direct investment in biopharma and raising capital in a challenging environment.
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.